Summary Primary chemotherapy in operable breast invasive carcinoma enables tumour reduction and conservative surgery. In order to search for one or more biological factors capable of predicting tumour behaviour under primary chemotherapy, and subsequent patient survival, an immunohistochemical study was performed with specific antibodies to p53, c-erbB-2 (Her-2/neu), Mibl (antiKi-67), pS2, GSTir, oestrogen receptors (ERs) and progesterone receptors (PRs). Core biopsies, obtained before primary chemotherapy, were available from a series of 128 breast invasive carcinomas treated between January 1985 and April 1989, with a median follow-up of 93.3 months. Univariate statistical analysis showed that negative ER detection by immunohistochemistry (IHC) was highly correlated with chemosensitivity (P=0.001). A high percentage of Mibl-positive tumour cells (>40%), as well as initial tumour size less than 4 cm, were also correlated with tumour responsiveness to chemotherapy (P=0.009 and P=0.03). By multivariate analysis IHC-ER, Mibl and initial tumour size were independent predictors, the last parameter being the most important. Concerning subsequent patient survival, c-erbB-2 overexpression, as detected by IHC, was significant with respect to overall survival (OS) (P=0.0006), disease-free interval (DFI) (P=0.03) and metastasis-free interval (MFI) (P=0.008) by univariate analysis. Furthermore, c-erbB-2 was the major independent prognostic factor for OS and MFI by multivariate analysis.
Since 1990 several reports have shown the effectiveness of primary chemotherapy in breast conservative surgery of resectable tumours larger than 3 cm (Bonnadonna et al., 1990; Gazet et al., 1991; Mauriac et al., 1991; Belembaogo et al., 1992; Calais et al., 1994; Smith et al., 1995) . This new therapeutic strategy, as well as those used in locally advanced breast disease, requires the validation of clinical and biological factors capable of predicting the tumoral response to cytotoxic therapy, and the subsequent clinical outcome. Until now most prognostic markers were designed and validated on primary surgery series of breast invasive carcinoma, complemented or not by adjuvant hormono-or chemotherapy. In these series it is sometimes difficult to grasp the meaning of the information provided by a prognostic factor in relation to the response to adjuvant therapy once the primary tumour has been removed. The primary chemotherapy regimens are elegant in vivo models where the informative value of a given tumour factor in relation to a certain cytotoxic drug can be assessed by simply analysing tumour shrinkage. Furthermore, the different criteria helping the clinician to predict patient outcome are somewhat different in the two therapeutic approaches, where one major information source, e.g. histological assessment of axillary lymph node involvement, is missing in the primary chemotherapy group. Pretherapeutic tumour core biopsies provide sufficient material to confirm the malignant and infiltrative nature of a breast tumour as well as to study and compare the predictive and prognostic values of different immunohistochemical factors.
At Bergonie Institute we have conducted a clinical trial on the effects of primary chemotherapy in conservative treatment of breast invasive carcinoma (Mauriac et al., 1991) . A set of 134 core biopsies was at our disposal to analyse different immunohistochemical factors including : the products of a tumour-suppressor gene, p53; an oncogene; cerbB-2 (or Her-2/neu); a detoxifying agent, glutathione-Stransferase pi (GSTm); a cell cycle nuclear protein, Ki67; an oestrogen-regulated protein, pS2 and finally, oestrogen and progesterone receptors. The aim of this study was to assess their predictive value for tumour response to primary chemotherapy and prognostic value for patient outcome and compare them with classical clinical and biological factors.
Materials and methods

Patient selection
Breast tumour core biopsies of 134 patients were retrieved from the files of the pathology department of Institute Bergonie and included in this immunohistochemical study. These patients belonged to the chemotherapy arm of a clinical trial on the effects of primary chemotherapy in conservative treatment of breast invasive carcinoma. The clinical trial was conducted at Bergonie Institute from January 1985 to April 1989 and included a total of 272 women (for details see Mauriac et al., 1991) . Briefly, the aim of this trial was to compare initial surgery and primary chemotherapy on primary metastasis-free operable breast tumours larger than 3 cm.
Before randomisation, two samples were obtained from each breast tumour. One sample was fixed in Bouin Hollande and embedded in paraffin before histological analysis. For the present study, six core biopsies of the initial 134 were excluded because of insufficient residual material. In the other sample oestrogen and progesterone receptor contents were determined by the dextran-coated charcoal method (DCC), with cut-off levels of 10 and 15 fmol mg-' of protein respectively.
Primary chemotherapy consisted of six courses, three with epirubicin, vincristine, methotrexate (EVM) followed by three with mitomycin C, thiotepa and vindesine (MTV). After completion of the sixth course, clinical examination and a radiographic mammogram were used to assess tumour regression. Locoregional treatment depended on this parameter.
Exclusive radiotherapy was performed in the case of complete regression. Conservative breast surgery with axillary lymph node dissection followed by radiotherapy were done in the cases of incomplete tumour regression with residual tumour measuring less than 2 cm in diameter. Mastectomy was performed in the remaining cases.
Histological examination was done on all excised tumours. Thus, 128 core biopsies and 86 excised tumours are analysed in this study.
Immunohistochemical assay
The IHC assays used in this study have been fully described elsewhere de Mascarel et al., 1995 determined semiquantitively from 0% to 100%. The threshold for p53, c-erbB-2 and GSTir positivity, was 1%; for pS2 positivity, 3%; and for IHC-ER and IHC-PR positivity, 10%. These optimal thresholds have already been determined in previous studies (MacGrogan et al., 1995; Quenel et al., 1995; de Mascarel et al., 1995) The log-rank test using the Kaplan-Meier method was again used to study the relationship between the different factors and prognosis expressed as 5 year probability of survival. A multivariate analysis using the Cox proportional hazard model permitted statistical evaluation of the different prognostic factors. All factors were entered in the Cox regression analysis whatever their P-value by univariate analysis; but only those with a P-value <1% were kept in the final model.
Clinical size of the tumours was assessed before treatment, before the second and fourth courses of chemotherapy and at the sixth. Patient follow-up was done quarterly for 2 years, twice a year and finally yearly. For overall survival (OS), survival duration was calculated from the randomisation date to death, or the date they were last known alive. All causes of death were considered as events. For metastasis-free interval (MFI) and for disease-free interval (DFI), time to failure was computed from the randomisation date until metastasis or relapse, or the date they were last known to be disease-free respectively. For DFI, local failure and/or metastasis were considered as events. The cut-off date for the current analysis was 1 May 1995 with a median follow-up of 93.3 months. Univariate analyses for survival were performed using the log-rank tests and BMDP software, program IL. Multivariate analyses were performed stepwise with the logistic regression or the Cox regression models using BMDP 2L.
Results
Clinical, pathological and biological characteristics of this series are listed in Table I Predictive value of 'hormone receptor status' The results of this study indicate that IHC detection of oestrogen receptors in breast carcinoma is also of major importance in determining tumoral response to primary chemotherapy. This is in accordance with previous reports showing a weak but significant link between ER-DCC status and tumoral chemosensitivity (Bonadonna et al., 1990; Mauriac et al., 1991; Belemboago et al., 1992) . In this study the predictive power of IHC-ER was much more important than that of DCC-ER concerning tumour regression (P=4x 10-4 vs P=0.1). Although the IHC and DCC-ER assays were highly correlated (P< 10-4), more ER-positive tumours were found by the IHC assay compared with the DCC assay (67% vs 46%). This may be explained by differences in tumour sampling, since the IHC-ER assay was performed on the paraffin tissue block containing the core biopsy in which the pathological diagnosis of invasive carcinoma was initially made, while the only control to confirm the presence of invasive carcinoma in the core biopsy sent for DCC-ER assay was done by cytological imprinting. Low tumour cellularity as well as low protein concentration of DCC-analysed samples may also explain the existance of DCC-ER-negative/IHC-ERpositive cases. This high rate of negative DCC-ER results with subsequent poor predictive value of DCC-ER may partially explain why previous studies did not find a relationship between DCC-ER and tumour regression.
In vitro and clinical studies have shown the increased sensitivity of ER-negative tumour cell lines and tumours towards cytotoxic agents, especially doxorubicin (Kaufman et al., 1980; Livingston et al., 1982; Mortimer et -al., 1985) . Epirubicin, a derivative of doxorubicin, was used in our study. ER-negative tumours have higher proliferation indexes than ER-positive tumours (Silvestri et al., 1979; Meyer et al., 1979) and should, therefore, be more chemosensitive. We found that, even if IHC-ER was negatively correlated with Mibl index (P= 0.01), IHC-ER was still an important independent factor in predicting tumour chemosensitivity, suggesting an independent effect, other than proliferative activity, in ER-negative tumours.
In our series PR status was not predictive for immediate tumour response to chemotherapy, but predicted subsequent (Raemakers et al., 1987) .
Predictive value of 'proliferative index'
We only found a significant difference in clinical response to primary chemotherapy in highly proliferating tumours showing a Mibl index over 40%. This observation confirms previous in vitro studies showing an increased sensitivity of highly proliferating tumours towards cytotoxic drugs in breast carcinoma cell lines (Weichselbaum et al., 1978; Tannock et al., 1978; Drewinko et al., 1981) . Similarly, previous clinical trials assessing S-phase fraction by flow cytometry demonstrated better clinical response to primary chemotherapy in tumours showing a high S-phase fraction (Spyratos et al., 1992; O'Reilly et al., 1992; Belemboago et al., 1992; Remvikos et al., 1993) . Surprisingly, the few clinical trials using the tritiated thymidine labelling index (TLI) as a method of assessing tumour proliferation did not show a significant difference for tumour response in tumours with a high TLI (Bonadonna et al., 1990; Daidone et al., 1991; Gardin et al., 1994 Predictive value of 'c-erbB-2 overexpression' Chemosensitivity and overexpression of c-erbB-2 in human breast carcinoma is a matter of controversy (for review see Klijn et al., 1993) . In our series c-erbB-2 was not a predictive factor for chemotherapeutic-induced tumour reduction or tumour resistance. On the other hand, c-erbB-2 was a major independent marker for predicting subsequent OS and MFI; patients overexpressing c-erb-2 having worse prognosis. (Whelan et al., 1989; Whelan and Hill, 1993) Predictive value of 'SBR grade' Surprisingly, in our series no significant predictive information was given by the assessment of tumour grade on the core biopsy before chemotherapy, even though SBR grade was correlated with major parameters in the series (Mibl, c-erbB-2 and IHC-ER). These results differ from those of another report on neoadjuvant chemotherapy (Jacquillat et al., 1990) , showing that tumour grading helps in assessing tumour chemosensitivity. But in the latter report, it is not clear whether tumour grading was histological or cytological or a combination of both. In our experience, SBR grading is one of the most important prognostic factors for predicting OS, MFI and DFI in node-negative and positive patients, in surgically removed, primary, metastasis-free, breast carcinoma (MacGrogan et al., 1995) . The size of the core biopsies analysed in this series was relatively small (mean length of 11.8 mm) making grading less comfortable than examining the entire section of a surgical tumour specimen. This is particularly true for assessment of mitotic index, which is usually done by us by counting the maximum number of mitoses in ten high-power fields (HPFs). In some cases in our series, ten HPFs of assessable invasive carcinoma were not available on the core biopsy analysed. In these cases mitotic index was predicted from the maximum number of mitoses counted in one field.
Predictive value of 'tumour response' Neither tumour response to primary chemotherapy nor local treatment were correlated with subsequent patient outcome in our series, in contrast to other reports (Feldman et al., 1986; Jacquillat et al., 1990; Scholl et al., 1991; Calais et al., 1994) . Ideally, tumour regression should have been confirmed by microscopic analysis, but this was impossible, because of the construction of our clinical trial. Feldman et al. (1986) performed a macroscopic as well as a microscopic analysis on all tumours and lymph nodes in their series. They found that absence of macroscopic evidence of residual gross cancer was a better indicator of improved survival than clinically assessed complete response. However, they did not use mammography to complement clinical examination. Furthermore, Feldman et al. (1986) , as well as Jacquillat et al. (1990) , included in their series inflammatory breast cancers for which clinical presentation and outcome differ from non-inflammatory breast cancers. The chemotherapy regimen in our series was identical for all patients, and was performed only initially. In the other series chemotherapeutic protocols are either heterogeneous, or sometimes complemented by hormone therapy or performed before and after surgery or radiotherapy.
Conclusion
In breast carcinoma, new therapeutic regimens are at the clinician's disposal for reducing tumour size before surgery in order to prevent mastectomy. New laboratory tools must be designed, in this perspective, that are capable of predicting tumour behaviour and patient survival. In this series of 128 core biopsies, we have shown that clinical measurement of tumour size, IHC assessment of ER content and determination of Mibl index before primary chemotherapy in breast invasive carcinomas, are major indicators of tumour chemosensitivity or resistance. Furthermore, detection of c-erbB-2 overexpression is the best prognostic factor for subsequent survival in patients treated by primary chemotherapy.
